Keith T Schmidt
Overview
Explore the profile of Keith T Schmidt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
207
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schlam I, Smith D, Peer C, Sissung T, Schmidt K, Tan M, et al.
NPJ Breast Cancer
. 2024 Sep;
10(1):84.
PMID: 39349477
Underrepresented populations' participation in clinical trials remains limited, and the potential impact of genomic variants on drug metabolism remains elusive. This study aimed to assess the pharmacokinetics (PK) and pharmacogenomics...
2.
Li Y, Vaughan K, Wang Y, Yu S, Bae E, Tamargo I, et al.
Geroscience
. 2024 Mar;
46(5):4397-4414.
PMID: 38532069
The endogenous incretins glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) possess neurotrophic, neuroprotective, and anti-neuroinflammatory actions. The dipeptidyl peptidase 4 (DPP-4) inhibitor sitagliptin reduces degradation of endogenous GLP-1 and...
3.
Peer C, Schmidt K, Arisa O, Richardson W, Paydary K, Goldstein D, et al.
J Clin Pharmacol
. 2023 Jan;
63(6):672-680.
PMID: 36624662
Atezolizumab, a humanized monoclonal antibody against programmed cell death ligand 1 (PD-L1), was initially approved in 2016, around the same time that the sponsor published the minimum serum concentration to...
4.
Li Y, Jin Y, Taheri H, Schmidt K, Gibson A, Buck S, et al.
Pharmaceutics
. 2022 Sep;
14(9).
PMID: 36145680
In recent years, various endogenous compounds have been proposed as putative biomarkers for the hepatic uptake transporters OATP1B1 and OATP1B3 that have the potential to predict transporter-mediated drug-drug interactions (DDIs)....
5.
Schmidt K, Karzai F, Bilusic M, Cordes L, Chau C, Peer C, et al.
Oncologist
. 2022 May;
27(9):718-e694.
PMID: 35640474
Background: Despite the clinical efficacy of enzalutamide monotherapy in patients with advanced prostate cancer, therapeutic resistance and disease progression are inevitable. We proposed a study to evaluate NLG207, a nanoparticle-drug...
6.
Cordes L, Schmidt K, Peer C, Chau C, Redmond E, Francis D, et al.
Oncologist
. 2021 Aug;
26(9):729-e1493.
PMID: 34333820
Lessons Learned: Limited evidence suggests an acceptable pharmacokinetic profile when enzalutamide is administered via a liquid formulation extracted from the commercially available liquid-filled soft-gelatin capsules. Tolerability may limit use in...
7.
Doan D, Schmidt K, Chau C, Figg W
Cancers (Basel)
. 2021 May;
13(9).
PMID: 33947030
Prostate cancer has entered into the era of precision medicine with the recent approvals of targeted therapeutics (olaparib and rucaparib). The presence of germline mutations has important hereditary cancer implications...
8.
Schmidt K, Huitema A, Chau C, Figg W
Nat Rev Urol
. 2021 Mar;
18(4):209-226.
PMID: 33742189
The introduction of second-generation androgen receptor antagonists (SG-ARAs) has greatly impacted the treatment of metastatic prostate cancer, providing tolerable and efficacious alternatives to chemotherapy. SG-ARAs provide similar therapeutic benefit to...
9.
Schmidt K, Chau C, Strope J, Huitema A, Sissung T, Price D, et al.
Mol Cancer Ther
. 2021 Feb;
20(5):915-924.
PMID: 33632874
Effective treatments for patients with metastatic castration-resistant prostate cancer following disease progression on enzalutamide are currently an unmet clinical need. Simultaneous inhibition of the hypoxia-inducible factor (HIF)-1α and androgen receptor...
10.
Tlemsani C, Takahashi N, Pongor L, Rajapakse V, Tyagi M, Wen X, et al.
Sci Transl Med
. 2021 Jan;
13(578).
PMID: 33504652
Because tobacco is a potent carcinogen, secondary causes of lung cancer are often diminished in perceived importance. To assess the extent of inherited susceptibility to small cell lung cancer (SCLC),...